Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia (Clinical Epigenetics, (2015), 7, 1, (2), 10.1186/s13148-014-0034-4)

Jessica M. Salmon; Michael Bots; Eva Vidacs; Kym L. Stanley; Peter Atadja; Johannes Zuber; Ricky W. Johnstone

doi:10.1186/s13148-020-00964-9

Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia (Clinical Epigenetics, (2015), 7, 1, (2), 10.1186/s13148-014-0034-4)

Jessica M. Salmon, Michael Bots, Eva Vidacs, Kym L. Stanley, Peter Atadja, Johannes Zuber, Ricky W. Johnstone

Research output: Contribution to journal › Comment / Debate › Other › peer-review

Abstract

Following publication of the original article [1], the authors identified an error in Fig. 2e. The correct Fig. 2 is given below. (Figure presented.).

Original language	English
Article number	178
Number of pages	2
Journal	Clinical Epigenetics
Volume	12
Issue number	1
DOIs	https://doi.org/10.1186/s13148-020-00964-9
Publication status	Published - Dec 2020
Externally published	Yes

Access to Document

10.1186/s13148-020-00964-9Licence: CC BY

Cite this

Salmon, J. M., Bots, M., Vidacs, E., Stanley, K. L., Atadja, P., Zuber, J., & Johnstone, R. W. (2020). Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia (Clinical Epigenetics, (2015), 7, 1, (2), 10.1186/s13148-014-0034-4). Clinical Epigenetics, 12(1), [178]. https://doi.org/10.1186/s13148-020-00964-9

Salmon, Jessica M. ; Bots, Michael ; Vidacs, Eva ; Stanley, Kym L. ; Atadja, Peter ; Zuber, Johannes ; Johnstone, Ricky W. / Correction to : Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia (Clinical Epigenetics, (2015), 7, 1, (2), 10.1186/s13148-014-0034-4). In: Clinical Epigenetics. 2020 ; Vol. 12, No. 1.

@article{f056a5e3f7904a928d4f683b5d9f588e,

title = "Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia (Clinical Epigenetics, (2015), 7, 1, (2), 10.1186/s13148-014-0034-4)",

abstract = "Following publication of the original article [1], the authors identified an error in Fig. 2e. The correct Fig. 2 is given below. (Figure presented.).",

author = "Salmon, {Jessica M.} and Michael Bots and Eva Vidacs and Stanley, {Kym L.} and Peter Atadja and Johannes Zuber and Johnstone, {Ricky W.}",

year = "2020",

month = dec,

doi = "10.1186/s13148-020-00964-9",

language = "English",

volume = "12",

journal = "Clinical Epigenetics",

issn = "1868-7083",

publisher = "BioMed Central",

number = "1",

}

Salmon, JM, Bots, M, Vidacs, E, Stanley, KL, Atadja, P, Zuber, J & Johnstone, RW 2020, 'Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia (Clinical Epigenetics, (2015), 7, 1, (2), 10.1186/s13148-014-0034-4)', Clinical Epigenetics, vol. 12, no. 1, 178. https://doi.org/10.1186/s13148-020-00964-9

Correction to : Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia (Clinical Epigenetics, (2015), 7, 1, (2), 10.1186/s13148-014-0034-4). / Salmon, Jessica M.; Bots, Michael; Vidacs, Eva; Stanley, Kym L.; Atadja, Peter; Zuber, Johannes; Johnstone, Ricky W.

In: Clinical Epigenetics, Vol. 12, No. 1, 178, 12.2020.

Research output: Contribution to journal › Comment / Debate › Other › peer-review

TY - JOUR

T1 - Correction to

T2 - Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia (Clinical Epigenetics, (2015), 7, 1, (2), 10.1186/s13148-014-0034-4)

AU - Salmon, Jessica M.

AU - Bots, Michael

AU - Vidacs, Eva

AU - Stanley, Kym L.

AU - Atadja, Peter

AU - Zuber, Johannes

AU - Johnstone, Ricky W.

PY - 2020/12

Y1 - 2020/12

N2 - Following publication of the original article [1], the authors identified an error in Fig. 2e. The correct Fig. 2 is given below. (Figure presented.).

AB - Following publication of the original article [1], the authors identified an error in Fig. 2e. The correct Fig. 2 is given below. (Figure presented.).

UR - http://www.scopus.com/inward/record.url?scp=85096191328&partnerID=8YFLogxK

U2 - 10.1186/s13148-020-00964-9

DO - 10.1186/s13148-020-00964-9

M3 - Comment / Debate

C2 - 33208184

AN - SCOPUS:85096191328

VL - 12

JO - Clinical Epigenetics

JF - Clinical Epigenetics

SN - 1868-7083

IS - 1

M1 - 178

ER -

Salmon JM, Bots M, Vidacs E, Stanley KL, Atadja P, Zuber J et al. Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia (Clinical Epigenetics, (2015), 7, 1, (2), 10.1186/s13148-014-0034-4). Clinical Epigenetics. 2020 Dec;12(1). 178. https://doi.org/10.1186/s13148-020-00964-9

Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia (Clinical Epigenetics, (2015), 7, 1, (2), 10.1186/s13148-014-0034-4)

Abstract

Access to Document

Other files and links

Research output

Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia

Cite this